
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. With bezuclastinib, its lead program, in clinical trials for advanced systemic mastocytosis and gastrointestinal stromal tumors, as well as new potential therapies in the pipeline, Cogent is well-positioned to address significant unmet medical needs and potentially attract acquisition interest. Positive Phase 3 clinical results and potential FDA approval in multiple indications could drive future growth and increase shareholder value, while the company has a strong financial position with enough cash to support operations into 2028.
Bears say
Cogent Biosciences is facing key risks to its valuation, including potential disappointing results from its CGT9486 program, competition from other companies, and regulatory/commercial risks. With its recent 4Q25 earnings showing reiteration of timelines and a strong cash balance, Cogent Biosciences is focused on submitting its NDA for bezuclastinib in NonAdvSM by the end of this month and in 2L GIST in April, as well as advancing its pipeline including planned IND submissions for CGT1815 and CGT1145. However, with potential challenges ahead and a lack of near-term catalysts, we have a negative outlook on COGT stock.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares